|
Abacus
Diagnostics |
|
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Links to more information: Products
Contact us on
|
Ipsogen is now recognised as a leader in the field of molecular testing for the monitoring of minimal residual disease in acute and chronic leukaemia. Ipsogen is currently leading the molecular diagnosis of leukaemia with a comprehensive range of Oncohaematology products and has in late stage development a breast cancer profiling diagnostic. FusionQuant®, ProfileQuant™, FusionChip®, and ProfileChip™ are proprietary diagnostic platforms designed to rapidly integrate new single markers or gene signatures emerging from our partnership and in-licensing efforts. PRODUCTSMLL FusionChip The MLL FusionChip® is a qualitative molecular diagnostic device that will confirm the presence of an MLL rearrangement, which gene is the fusion partner and the breakpoint position of the partner gene. The protocol is based on the amplification and detection of fusion transcripts by means of a reverse transcription followed by an anchored PCR and hybridisation on the MLL FusionChip A colorimetric reaction visually shows the presence of an MLL translocation and allows the identification of the associated partner gene.
The ready to use FusionQuant® kits contain primers and probe mix and standards specific for the fusion gene and the ABL control gene. These unique molecular kits will standardise, detect and quantify various fusion gene transcripts in acute and chronic leukaemia samples.
ProfileQuant™ The Ipsogen ProfileQuant™ WT1 Kit is a unique quantitative molecular kit aimed at standardising, detecting and quantifying the WT1 gene transcript in human cells. The WT1 ProfileQuant™ Kit is a research tool intended for the accurate normalised quantification of WT1 gene transcripts in human cells. This kit contains primers and probe mixes and standards specific for the WT1 gene and the ABL control gene.
The range of FusionQuant® Standards includes control gene standards intended for the quantification of mRNA and fusion gene standards intended for the quantification of individual fusion genes in the RQ-PRC reaction. Plasmid standard curves offer the ability to directly quantify the copy number of the transcripts and are suitable calibrators for intralaboratory normalisation of RQ-PCR analysis.
Ipsogen is pleased to announce a new addition to the expanding range of IVD clinical diagnostic products for Molecular Haematology. The FusionQuant™ kit range now includes a ready-to-use PML-RARA bcr1 Kit for fusion gene quantification by real time quantitative PCR. This kit contains specific EAC primers and probe mixes plus standards for the PML-RARA bcr1 Fusion Gene and the ABL Control Gene. The PML-RARA kit complies fully with the European in vitro diagnostic medical device directive, as a CE marked product and allows the quantification of PML-RARA fusion gene transcripts providing independent prognostic information suitable for monitoring and adapting treatment The availability of such a kit also facilitates data comparison among different centres, allowing the possibility to define a threshold where a patient is likely to relapse, and to assess the impact of early therapeutic intervention based on the kinetics of PML-RARA fusion gene transcript expression. |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
